An advanced personalized mRNA cancer treatment called intismeran autogene (mRNA-4157), developed jointly by Moderna and Merck, successfully met its goals in a major late-stage clinical trial when combined with the immunotherapy drug Keytruda. The treatment significantly reduced the risk of melanoma returning or spreading after surgery.
Messenger RNA (mRNA) is a single-stranded molecule that carries genetic instructions copied from DNA in the cell nucleus to the cytoplasm, where ribosomes use the code to build proteins.